Answers are grounded in this paper and cite their sources.
INTRODUCTION: Wide variance in myelodysplastic syndrome/neoplasm (MDS) disease biology informs risk and ultimately management, which leverages a relatively limited number of agents with insufficient rate and duration of meaningful clinical response. The development of novel agents is required to address the significant unmet clinical needs of patients with these malignant diseases. AREAS COVERED: This review focuses on novel agents that stem from a progressive understanding of MDS pathobiology and for which there are available pre-clinical and/or clinical data. A literature search was conducted using PubMed/MEDLINE, Embase, and Web of Science databases; abstracts from major hematology-oncology conferences were reviewed, and the clinicaltrials.gov registry was queried for active trials. The search used the key word 'myelodysplastic syndrome' and included articles published in English up to 10 May 2026. EXPERT OPINION: An increasing understanding of the biological underpinnings of MDS pathogenesis and progression has yielded the availability of several efficacious synthetic molecules. Efforts to target both select biological subgroups and broader mechanisms of disease are underway in both classical later-line monotherapy settings and frontline combinations with available agents. Correlative analyses from past/ongoing studies and inclusive, yet optimized trial designs will aid the pursuit of getting more effective therapies to MDS populations in need.
No takes yet. Share an insight, caveat, or question.
Rory Michael Shallis (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: